Doripenem + Imipenem-Cilastatin + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Ventilator-Associated Pneumonia
Conditions
Ventilator-Associated Pneumonia
Trial Timeline
Apr 1, 2008 → Jun 1, 2011
NCT ID
NCT00589693About Doripenem + Imipenem-Cilastatin + Placebo
Doripenem + Imipenem-Cilastatin + Placebo is a phase 3 stage product being developed by Johnson & Johnson for Ventilator-Associated Pneumonia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00589693. Target conditions include Ventilator-Associated Pneumonia.
What happened to similar drugs?
1 of 2 similar drugs in Ventilator-Associated Pneumonia were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00589693 | Phase 3 | Terminated |
Competing Products
4 competing products in Ventilator-Associated Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem | Johnson & Johnson | Phase 2 | 35 |
| Ceftolozane/Tazobactam + Piperacillin/Tazobactam | Merck | Phase 3 | 32 |
| Vancomycin + Linezolid | Pfizer | Approved | 43 |
| IC43 + Placebo | Valneva SE | Phase 2 | 29 |